抗病毒治疗在HBV相关肝癌综合治疗中的作用*

doi:10.3969/j.issn.1672-5069.2015.02.002

Abstract

Zhou Weiping, Yin Lei, Wu Mengchao. Antiviral therapy in patients with hepatitis B viral infection-related primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 115-117.

[1] Chen CJ,Yang HI,Su J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006,295（1）:65-73.
[2] Wu JC,Huang YH,Chau GY,et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol,2009,51（5）:890-897.
[3] Lai CL,Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology,2013,57（1）:399-408.
[4] Huang G,Lau WY,Shen F,et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma. World J Surg,2014,38（9）:2370-2376.
[5] Huang G,Yang Y,Shen F,et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV DNA load. Ann Surg Oncol,2013,20（5）:1482-1490.
[6] Lee JI,Kim JK,Chang HY,et al. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. J Gastroenterol Hepatol,2014,29（5）:1019-1027.
[7] Yeo W,Zee B,Zhong S,et al. Comprehensive analysis of risk factors associating with epatitis B virus （HBV） reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004,90（7）:1306-1311.
[8] Huang W,Zhang W,Fan M,et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.Cancer Sci,2014,105（6）:697-703.
[9] Jang JW,Choi JY,Bae SH,et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology,2006,43（2）:233-240.
[10] Kim JH,Park JW,Kim TH,et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys,2007,69（3）:813-819.
[11] Yeo W,Lam KC,Zee B,et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol,2004,15（11）:1661-1666.
[12] Urata Y,Kubo S,Takemura S,et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.J Hepatobiliary Pancreat Sci,2012,19（6）:685-696.
[13] Liaw YF,Sung JJ,Chow WC,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351（15）:1521-1531.
[14] Lai CL,Chien RN,Leung NW,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med,1998,339（2）:61-68.
[15] Lai CL,Gane E,Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357（25）:2576-2588.
[16] Chang TT,Liaw YF,Wu SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52（3）:886-893.
[17] Wong JS, Wong GL,Tsoi KK,et al. Meta-analysis:the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther,2011,33（10）:1104-1112.
[18] Wu CY,Chen YJ,Ho HJ,et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA,2012,308（18）:1906-1914.
[19] Koda M,Nagahara T,Matono T,et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med,2009,48（1）:11-17.
[20] Yin J,Li N,Han Y,et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study. J Clin Oncol, 2013, 31（29）:3647-3655.
[21] Lao XM,Luo G,Ye LT,et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int,2013,33（4）:595-604.
[22] Dan JQ,Zhang YJ,Huang JT,et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma:a retrospective study. Eur J Surg Oncol,2013,39（8）:865-872.
[23] Kim YS,Lim HK,Rhim H,et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol,2013,58（1）:89-97.
[24] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[25] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）. 临床肝胆病杂志,2011,27（11）:1141-1159.

Antiviral therapy in patients with hepatitis B viral infection-related primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Liu Xing, Zhao Shuli, Zhang Dianlong. Effect of sevoflurane inhalation on hepatic ischemia-reperfusion injury in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(5): 728-731.